From: Risk of breast cancer in Lynch syndrome: a systematic review
Single case reports | Â | Â | Â | Â | Â |
---|---|---|---|---|---|
Author | Year | Country | Method | MMR gene mutated/absence of MMR protein in IHC/MSI status | Age, years |
Boyd et al. [25] | 1999 | USA | MSI, IHC | MLH1/MLH1 loss/MSI-H | 71 (male) |
Caluseriu et al. [26] | 2001 | Italy | MSI | MLH1/NR/MSS | Â |
Westenend et al. [27] | 2005 | The Netherlands | MSI, IHC | MSH2/MSH2 and MSH6/MSI-H | 49 |
Akoum et al. [28] | 2009 | Lebanon | MSI, IHC | MSH2/MSH2 and MSH6/MSS | 26 |
D'Arcy et al. [29] | 2011 | USA | IHC | MSH2/MSH2 and MSH6/NR | 74 |
Case series | Â | Â | Â | Â | Â |
Author | Year | Country | Method | Number of MMR-deficient breast cancers/ number of MMR gene mutation carriers | Age, years, mean ± SD |
Risinger et al. [30] | 1996 | USA | MSI, IHC | 3/5 (60%) | NR |
Muller et al. [31] | 2002 | USA | MSI, IHC | 0/3 (0%) | NR |
de Leeuw et al. [32] | 2003 | The Netherlands | MSI | 7/11 (64%) | 43.6 ± 9.2 |
Blokhuis et al. [33] | 2008 | South Africa | MSI, IHC | 5/6 (83%) | 51.8 ± 16.9 |
Shanley et al. [34] | 2009 | Australia | MSI, IHC | 3/4 (75%) | 65.0 ± 12.3 |
Jensen et al. [35] | 2010 | Denmark | IHC | 7/16 (44%) | 50.4 ± 13.1 |
Walsh et al. [36] | 2010 | Australia, USA, Canada | MSI, IHC | 18/35 (51%) | 57.5 ± 8.1 |
Buerki et al. [37] | 2012 | Switzerland | MSI, IHC | 6/7 (86%) | 53.7 ± 15.2 |
Lotsari et al. [38] | 2012 | Finland | MSI, IHC | 13/20 (65%) | 52.7 ± 7.0 |
Grandval et al. [39] | 2012 | France | MSI | 0/15 (0%) | 53.1 ± 10.0 |